Sectoral Asset Management Has Decreased Its Loxo Oncology (LOXO) Position as Shares Rose; Foundation Resource Management Lowered Cenovus Energy (CVE) Stake as Shares Declined

April 15, 2018 - By Dolores Ford

Loxo Oncology, Inc. (NASDAQ:LOXO) Logo

Foundation Resource Management Inc decreased its stake in Cenovus Energy Inc. (CVE) by 13.74% based on its latest 2017Q4 regulatory filing with the SEC. Foundation Resource Management Inc sold 90,959 shares as the company’s stock declined 6.72% with the market. The institutional investor held 571,061 shares of the oil & gas production company at the end of 2017Q4, valued at $5.21M, down from 662,020 at the end of the previous reported quarter. Foundation Resource Management Inc who had been investing in Cenovus Energy Inc. for a number of months, seems to be less bullish one the $12.11 billion market cap company. The stock increased 2.12% or $0.21 during the last trading session, reaching $10.1. About 6.51 million shares traded or 43.88% up from the average. Cenovus Energy Inc. (NYSE:CVE) has declined 35.61% since April 15, 2017 and is downtrending. It has underperformed by 47.16% the S&P500.

Jerome Pfund decreased its stake in Loxo Oncology Inc (LOXO) by 37.94% based on its latest 2017Q4 regulatory filing with the SEC. Sectoral Asset Management Inc sold 93,041 shares as the company’s stock rose 30.92% while stock markets declined. The hedge fund run by Jerome Pfund held 152,185 shares of the health care company at the end of 2017Q4, valued at $12.81 million, down from 245,226 at the end of the previous reported quarter. Sectoral Asset Management Inc who had been investing in Loxo Oncology Inc for a number of months, seems to be less bullish one the $3.69 billion market cap company. The stock decreased 2.57% or $3.25 during the last trading session, reaching $122.99. About 305,913 shares traded. Loxo Oncology, Inc. (NASDAQ:LOXO) has risen 146.80% since April 15, 2017 and is uptrending. It has outperformed by 135.25% the S&P500.

Sectoral Asset Management Inc, which manages about $3.30B and $800.30 million US Long portfolio, upped its stake in Cigna Corp (NYSE:CI) by 22,000 shares to 67,615 shares, valued at $13.73M in 2017Q4, according to the filing. It also increased its holding in Celgene Corp (NASDAQ:CELG) by 102,898 shares in the quarter, for a total of 231,830 shares, and has risen its stake in Regeneron Pharmaceuticals (NASDAQ:REGN).

Analysts await Loxo Oncology, Inc. (NASDAQ:LOXO) to report earnings on May, 8. They expect $-0.44 EPS, up 54.17% or $0.52 from last year’s $-0.96 per share. After $-0.69 actual EPS reported by Loxo Oncology, Inc. for the previous quarter, Wall Street now forecasts -36.23% EPS growth.

Investors sentiment decreased to 0.97 in 2017 Q4. Its down 0.76, from 1.73 in 2017Q3. It turned negative, as 29 investors sold LOXO shares while 43 reduced holdings. 23 funds opened positions while 47 raised stakes. 124.82 million shares or 329.48% more from 29.06 million shares in 2017Q3 were reported. Parametric Portfolio Associates Ltd Llc accumulated 14,144 shares. Parallax Volatility Advisers LP stated it has 3,486 shares or 0% of all its holdings. Royal National Bank Of Canada holds 0% of its portfolio in Loxo Oncology, Inc. (NASDAQ:LOXO) for 226 shares. Moreover, Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in Loxo Oncology, Inc. (NASDAQ:LOXO) for 1,083 shares. Legal & General Plc owns 12,770 shares. Financial Bank Of New York Mellon Corporation holds 105,231 shares. Ubs Asset Management Americas invested in 0.02% or 211,234 shares. Victory Capital Mngmt, Ohio-based fund reported 450,947 shares. Moreover, Pinnacle Assocs Ltd has 0.01% invested in Loxo Oncology, Inc. (NASDAQ:LOXO). Franklin Resources Inc holds 0.02% or 494,101 shares. Pnc Financial Service Gp Inc stated it has 0% in Loxo Oncology, Inc. (NASDAQ:LOXO). Regis Mgmt Limited Liability Co reported 3,457 shares stake. Alabama-based Weiss Multi has invested 0.04% in Loxo Oncology, Inc. (NASDAQ:LOXO). Blackrock owns 1.84M shares. Amundi Pioneer Asset has 80,571 shares for 0.01% of their portfolio.

Since October 16, 2017, it had 0 buys, and 16 insider sales for $70.72 million activity. $1.22 million worth of Loxo Oncology, Inc. (NASDAQ:LOXO) was sold by Bilenker Joshua H. on Thursday, December 14. Another trade for 250,000 shares valued at $20.63M was made by Bonita David P on Friday, December 8. The insider Naider Avi Z. sold $450,000. $20.13 million worth of Loxo Oncology, Inc. (NASDAQ:LOXO) was sold by AISLING CAPITAL III LP on Tuesday, December 19. Burstein Jennifer sold $131,243 worth of stock. ORBIMED ADVISORS LLC sold $20.63 million worth of stock.

Among 11 analysts covering Loxo Oncology Inc (NASDAQ:LOXO), 9 have Buy rating, 1 Sell and 1 Hold. Therefore 82% are positive. Loxo Oncology Inc had 34 analyst reports since July 29, 2015 according to SRatingsIntel. Oppenheimer initiated the stock with “Buy” rating in Thursday, February 22 report. The stock has “Buy” rating by Citigroup on Monday, June 5. Stifel Nicolaus maintained the stock with “Buy” rating in Wednesday, September 27 report. The firm has “Buy” rating given on Monday, June 5 by Cowen & Co. The stock of Loxo Oncology, Inc. (NASDAQ:LOXO) has “Buy” rating given on Monday, June 5 by Stifel Nicolaus. Citigroup initiated Loxo Oncology, Inc. (NASDAQ:LOXO) on Monday, January 18 with “Buy” rating. The firm has “Buy” rating given on Wednesday, March 16 by Stifel Nicolaus. The firm earned “Buy” rating on Friday, January 15 by Citigroup. The stock of Loxo Oncology, Inc. (NASDAQ:LOXO) earned “Overweight” rating by Morgan Stanley on Friday, October 6. The rating was maintained by Citigroup with “Buy” on Friday, October 20.

Analysts await Cenovus Energy Inc. (NYSE:CVE) to report earnings on April, 25. They expect $-0.04 earnings per share, 0.00% or $0.00 from last year’s $-0.04 per share. After $-0.35 actual earnings per share reported by Cenovus Energy Inc. for the previous quarter, Wall Street now forecasts -88.57% EPS growth.

Among 16 analysts covering Cenovus Energy Inc (NYSE:CVE), 7 have Buy rating, 2 Sell and 7 Hold. Therefore 44% are positive. Cenovus Energy Inc had 27 analyst reports since July 21, 2015 according to SRatingsIntel. Goldman Sachs upgraded the stock to “Buy” rating in Tuesday, January 26 report. RBC Capital Markets maintained the shares of CVE in report on Thursday, April 28 with “Outperform” rating. Bank of America initiated the shares of CVE in report on Friday, August 19 with “Neutral” rating. The company was maintained on Friday, October 13 by Morgan Stanley. The stock of Cenovus Energy Inc. (NYSE:CVE) earned “Underperform” rating by Macquarie Research on Tuesday, January 24. The rating was maintained by JP Morgan on Tuesday, December 15 with “Neutral”. The stock of Cenovus Energy Inc. (NYSE:CVE) earned “Neutral” rating by Nomura on Thursday, January 21. UBS downgraded the shares of CVE in report on Tuesday, January 26 to “Neutral” rating. The firm has “Neutral” rating by Macquarie Research given on Thursday, March 30. Goldman Sachs upgraded the shares of CVE in report on Friday, March 11 to “Conviction Buy” rating.

Loxo Oncology, Inc. (NASDAQ:LOXO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>